Clinical Trials Logo

Helicobacter Pylori Infection clinical trials

View clinical trials related to Helicobacter Pylori Infection.

Filter by:

NCT ID: NCT03779074 Completed - Clinical trials for Helicobacter Pylori Infection

Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies

Start date: September 3, 2018
Phase: Phase 3
Study type: Interventional

Both hybrid and high-dose dual therapies developed by the scholars from Taiwan can achieve a high eradication rate for clarithromycin-resistant strains, and have a great potential to replace bismuth quadruple therapy in the treatment of H. pylori infection.

NCT ID: NCT03757650 Completed - Clinical trials for Helicobacter Pylori Infection

THE EFFECT OF HELICOBACTER PYLORI ERADICATION THERAPY TO GASTRIC WALL THICKNESS BEFORE THE LAPAROSCOPIC SLEEVE GASTRECTOMY

Start date: October 1, 2018
Phase: Phase 4
Study type: Interventional

Laparoscopic sleeve gastrectomy is one of the most popular bariatric surgery in the world. The most important complication about this surgery that the leakage from the stapler line because of the inconvenient stapler choice..The stapler colour has to be chosen to the gastric wall thickness. It is not known well that the effect of Helicobacter pylori to gastric wall thickness Nobody pay any attention about being Helicobacter pylori positive when they are choosing stapler colour during the Laparoscopic sleeve gastrectomy so that everybody use the same type of stapler in Helicobacter pylori positive and negative patients during the Laparoscopic sleeve gastrectomy .Because of this inconvenient staplers use in the Laparoscopic sleeve gastrectomy the risk of leakage would be increase. Purpose of this research is that what is the effect of Helicobacter pylori to the gastric wall thickness and if the patients who will undergo Laparoscopic sleeve gastrectomy take the Helicobacter pylori eradication therapy before the surgery will gastric wall thickness increase or decrease. .

NCT ID: NCT03730766 Recruiting - Clinical trials for Helicobacter Pylori Infection

Analysis of the Impact of Helicobacter Pylori on Salivary Microbiome in Adults

Start date: August 1, 2018
Phase: Phase 4
Study type: Interventional

Helicobacter pylori (H. pylori), a bacteria transmitted from human to human through upper digestive tract as well as fecal-oral transmission, had infected more than half of people around the world. However, the quantity of H. pylori in oral cavity and its influence on oral microbiota remains to be unclear. The aim of the present study was to examine the effects of H. pylori infection as well as its eradication on oral microbiota.

NCT ID: NCT03726099 Recruiting - Clinical trials for Helicobacter Pylori Infection

Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection

Start date: March 15, 2019
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate efficacy of a 14-day concomitant therapy for the third-line treatment of Helicobacter pylori infection, and whether it is safe while maintaining an ideal eradication rates.

NCT ID: NCT03722433 Recruiting - Clinical trials for Helicobacter Pylori Infection

Probiotics in the Reduction of Adverse Effects and Dysbiosis of H. Pylori Eradication

Start date: August 29, 2018
Phase: Phase 4
Study type: Interventional

The investigators aimed to assess the effect of probiotic supplementation with Vigiis 101-LAB during H. pylori eradication therapy with 14-day sequential therapy in the reduction of adverse effects and the restoration of the dysbiosis.

NCT ID: NCT03708848 Completed - Clinical trials for Helicobacter Pylori Infection

Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy

Start date: December 5, 2018
Phase: Phase 4
Study type: Interventional

Increasing drug resistance presents a significant challenge to the efficacies of common empiric eradication regimens for Helicobacter pylori treatment in the mainland of China. Tailored therapy may be the best choice to achieve good efficacy, especially in patients with penicillin allergy. Few studies had evaluated the patients with penicillin allergy.This study is designed to evaluate the efficacy and safety of antibiotic sensitivity-based tailored therapy for Helicobacter pylori treatment in the patients with penicillin allergy.

NCT ID: NCT03688828 Completed - Clinical trials for Helicobacter Pylori Infection

Evaluation of Saccharomyces Boulardii Combined With Standard Quadruple Therapy for Eradication of Helicobacter Pylori

Start date: November 11, 2018
Phase: N/A
Study type: Interventional

The eradication rate of standard quadruple therapy has become less successful due to low compliance and high resistance to the antibiotics. Therefore, it is necessary to develop new treatment strategies that increase the eradication rate and reduce adverse effects. The aims of this prospective study is to investigate the efficacy of Saccharomyces Boulardii sachets for eradication of Hp, compared with standard quadruple therap.

NCT ID: NCT03665428 Completed - Clinical trials for Helicobacter Pylori Infection

Helicobacter Pylori Eradication Rates of Bismuth-containing Quadruple Therapy vs Modified Quadruple Therapy in Korea

Start date: July 16, 2018
Phase: Phase 4
Study type: Interventional

South Korea has the highest incidence of gastric cancer worldwide and Helicobacter pylori infection is still prevalent. Clarithromycin-containing triple therapy is still the primary therapy approved by the Korean government. However, studies of antibiotic resistance has shown that regional resistance pattern to antibiotics such as clarithromycin, metronidazole, or quinolone. Recent study in Korea has shown that modified-quadruple therapy has comparable eradication rate to concomitant therapy. However, there has been no comparable study of modified-quadruple therapy with bismuth-containing quadruple therapy. The aim of this study is to compare the eradication rate of modified-quadruple therapy and bismuth-containing quadruple therapy with presenting phenotypic and genotypic antibiotic resistance profile.

NCT ID: NCT03658746 Completed - Clinical trials for Helicobacter Pylori Infection

Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection

Start date: January 1, 2019
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess efficacy of 14-day antimicrobial susceptibility test guided quadruple therapy for the rescue treatment of Helicobacter pylori infection, then comparing it with 14-day empirical therapy according to personal medication history.

NCT ID: NCT03658733 Not yet recruiting - Clinical trials for Helicobacter Pylori Infection

A Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection

Start date: December 15, 2018
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess efficacy of a new 14-day sequential therapy for the rescue treatment of refractory Helicobacter pylori infection, and whether it is safe while maintaining an ideal eradication rates. The researchers also want to testify whether a double-dose rabeprazole has equal efficacy to double-dose esomeprazole to provide sufficient acid inhibition.